SG10201900954SA - Heterocycles as Modulators of Kinase Activity - Google Patents

Heterocycles as Modulators of Kinase Activity

Info

Publication number
SG10201900954SA
SG10201900954SA SG10201900954SA SG10201900954SA SG10201900954SA SG 10201900954S A SG10201900954S A SG 10201900954SA SG 10201900954S A SG10201900954S A SG 10201900954SA SG 10201900954S A SG10201900954S A SG 10201900954SA SG 10201900954S A SG10201900954S A SG 10201900954SA
Authority
SG
Singapore
Prior art keywords
heterocycles
modulators
kinase activity
cancer
manufacture
Prior art date
Application number
SG10201900954SA
Inventor
Ruoxi Lan
Xiaoling Chen
Yufang Xiao
Bayard R Huck
Andreas Goutopoulos
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG10201900954SA publication Critical patent/SG10201900954SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Heterocycles as Modulators of Kinase Activity The invention provides novel heterocyclic amines according to Formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. (I)
SG10201900954SA 2013-03-11 2014-03-10 Heterocycles as Modulators of Kinase Activity SG10201900954SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361776440P 2013-03-11 2013-03-11

Publications (1)

Publication Number Publication Date
SG10201900954SA true SG10201900954SA (en) 2019-02-27

Family

ID=50440836

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201900954SA SG10201900954SA (en) 2013-03-11 2014-03-10 Heterocycles as Modulators of Kinase Activity
SG11201505999VA SG11201505999VA (en) 2013-03-11 2014-03-10 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201505999VA SG11201505999VA (en) 2013-03-11 2014-03-10 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity

Country Status (17)

Country Link
US (2) US9458134B2 (en)
EP (1) EP2970201B1 (en)
JP (1) JP6483656B2 (en)
KR (1) KR20150124957A (en)
CN (1) CN105209454A (en)
AR (1) AR095202A1 (en)
AU (1) AU2014228385B2 (en)
BR (1) BR112015021324A2 (en)
CA (1) CA2902755C (en)
ES (1) ES2746756T3 (en)
HK (1) HK1218756A1 (en)
IL (1) IL240875B (en)
MX (1) MX370448B (en)
RU (1) RU2674261C2 (en)
SG (2) SG10201900954SA (en)
WO (1) WO2014143612A1 (en)
ZA (1) ZA201505749B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970201B1 (en) * 2013-03-11 2019-06-19 Merck Patent GmbH 6-[4-(1h-imidazol-2-yl)piperidin-1-yl]pyrimidin-4-amine derivatives as modulators of kinase activity
JP6560243B2 (en) * 2014-02-11 2019-08-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Pyrimidineimidazolamine as a modulator of kinase activity
RU2733401C2 (en) * 2014-04-03 2020-10-01 Мерк Патент Гмбх Combinations of anti-cancer medicines
BR112018073721B1 (en) * 2016-05-20 2023-12-05 Taiho Pharmaceutical Co., Ltd 5H-PYRROLE[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE OR A SALT THEREOF, ITS USE, ANTITUMOR AGENT AND PHARMACEUTICAL COMPOSITION
CN110922354B (en) * 2019-12-12 2023-05-02 丽水绿氟科技有限公司 Chemical resolution preparation method of 1-R-3-haloperidol-4-carboxylic acid and product thereof
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
ES2399047T3 (en) * 2002-09-20 2013-03-25 Merck Serono Sa Piperazine derivatives and use procedure
JP2006522124A (en) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド Compositions useful as inhibitors of protein kinases
CN100412066C (en) 2003-09-30 2008-08-20 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
JP4800216B2 (en) 2003-10-24 2011-10-26 エグゼリクシス， インコーポレイテッド p70S6 kinase modulator and methods of use
CN1902200A (en) 2003-11-21 2007-01-24 诺瓦提斯公司 1h-imidazoquinoline derivatives as protein kinase inhibitors
DE602004024115D1 (en) 2003-12-09 2009-12-24 Us Gov Health & Human Serv METHOD FOR SUPPRESSING AN IMMUNE RESPONSE OR TREATING PROLIFERATIVE DISEASES
GB0403606D0 (en) * 2004-02-18 2004-03-24 Novartis Ag Organic compounds
JP5213229B2 (en) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド Kinase modulators and methods of use
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
AR064416A1 (en) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd DERIVATIVES OF PURINE, PIRIDINE AND PYRIMIDINE CONDENSED WITH HETEROCICLES, MODULATORS OF PKA AND / OR PKB, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES.
UA99284C2 (en) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані P70 s6 kinase inhibitors
AR074072A1 (en) 2008-11-11 2010-12-22 Lilly Co Eli COMPOSITE OF IMIDAZOL -PIPERIDIN -PIRROL-PIRIMIDIN-6-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT MULTIFORM GLIOBLASTOMA
WO2010056574A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
MX2011005002A (en) * 2008-11-11 2011-05-25 Lilly Co Eli P70 s6 kinase inhibitor and egfr inhibitor combination therapy.
PT2396307E (en) 2009-02-11 2015-02-04 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
MX2012004780A (en) * 2009-10-23 2012-08-23 Lilly Co Eli Akt inhibitors.
UA110113C2 (en) 2010-07-29 2015-11-25 BICYCLIC AZAGETEROCYCLIC CARBOXAMIDES
SG186199A1 (en) * 2010-07-29 2013-01-30 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
RS55204B1 (en) 2010-11-24 2017-01-31 Merck Patent Gmbh Quinazoline carboxamide azetidines
RS63418B1 (en) * 2011-06-10 2022-08-31 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
AU2012284184B2 (en) * 2011-07-18 2017-03-09 Merck Patent Gmbh Benzamides
EP2755958B9 (en) * 2011-09-12 2018-02-28 Merck Patent GmbH Aminopyrimidine derivatives for use as modulators of kinase activity
SG10201606301YA (en) * 2011-09-12 2016-09-29 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
EA201791073A1 (en) * 2011-12-22 2017-09-29 Мерк Патент Гмбх NEW HETEROCYCLIC CARBOXAMIDES AS KINAZ ACTIVITY MODULATORS
EP2892534B8 (en) * 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014078634A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Novel imidazol-piperidinyl derivatives as modulators of kinase activity
EP2970201B1 (en) * 2013-03-11 2019-06-19 Merck Patent GmbH 6-[4-(1h-imidazol-2-yl)piperidin-1-yl]pyrimidin-4-amine derivatives as modulators of kinase activity
JP6560243B2 (en) * 2014-02-11 2019-08-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Pyrimidineimidazolamine as a modulator of kinase activity
WO2015134536A1 (en) * 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor

Also Published As

Publication number Publication date
US9458134B2 (en) 2016-10-04
MX370448B (en) 2019-12-13
US20160016936A1 (en) 2016-01-21
RU2015143160A3 (en) 2018-03-01
US9867826B2 (en) 2018-01-16
MX2015011660A (en) 2015-12-16
IL240875B (en) 2020-08-31
JP6483656B2 (en) 2019-03-13
KR20150124957A (en) 2015-11-06
RU2015143160A (en) 2017-04-18
AU2014228385B2 (en) 2018-08-09
EP2970201B1 (en) 2019-06-19
HK1218756A1 (en) 2017-03-10
CA2902755C (en) 2021-02-16
AR095202A1 (en) 2015-09-30
US20160361316A1 (en) 2016-12-15
ES2746756T3 (en) 2020-03-06
BR112015021324A2 (en) 2017-07-18
EP2970201A1 (en) 2016-01-20
RU2674261C2 (en) 2018-12-06
IL240875A0 (en) 2015-10-29
CA2902755A1 (en) 2014-09-18
SG11201505999VA (en) 2015-08-28
CN105209454A (en) 2015-12-30
JP2016512509A (en) 2016-04-28
WO2014143612A1 (en) 2014-09-18
ZA201505749B (en) 2017-01-25
AU2014228385A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12015500525A1 (en) Formulations of enzalutamide
MX2016010571A (en) Pyrazolyl-ureas as kinase inhibitors.
MX2014002836A (en) Aminopyrimidine derivatives for use as modulators of kinase activity.
IN2015DN00827A (en)
MX2015000129A (en) Pyrimidine pyrazolyl derivatives.
MX346095B (en) Novel imidazole amines as modulators of kinase activity.
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
MX2014007895A (en) Inhibitors of iap.
MX2014007364A (en) Novel heterocyclic carboxamides as modulators of kinase activity.
MX2016010268A (en) Pyrimidine imidazole amines as modulators of kinase activity.
MX2017005669A (en) Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof.
LV14779A (en) 4-amino-2-(1,2,3-triazol-1-yl)-quinazoline derivatives and synthesis method thereof